Reimbursement of medicines in belgium: Role of evidence-based medicine

Acta Clinica Belgica

Volumn 64, Issue 2, 2009, Pages 120-128

  Wilder, P B Van ^a,b,d   Dupont, A G ^b,c  

^a RIZIV Rijksinstituut voor Ziekteen Invaliditeitsverzekering   (Belgium)

^b CommissieTegemoetkoming Geneesmiddelen ^*

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d CTC   (Belgium)

Author keywords

Added therapeutic value; Evidence; Medicines; Reimbursement

Indexed keywords

GENERIC DRUG;

ADDED THERAPEUTIC VALUE; ARTICLE; BELGIUM; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; EUROPEAN UNION; EVALUATION; EVIDENCE BASED MEDICINE; REIMBURSEMENT; STATISTICS;

BELGIUM; COST SAVINGS; DRUGS, GENERIC; EVIDENCE-BASED MEDICINE; HUMANS; REIMBURSEMENT MECHANISMS; RETROSPECTIVE STUDIES;

EID: 64949195991     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dir.2001/83/ECof the European Parliament and of the Council. Official Journal of the European Communities. 2001; L311:67-128.
2. Dir. 89/105/EEC of the European Council. Official Journal of the European Communities. 1989; L40:65-71.
3. RIZIV, Geneesmiddelen en andere verstrekkingen, via http://inami.fgov.be/ drug/nl/drugs/reglementation/ar-20011221/pdf/ arkb20011221.pdf (accessed Feb 27th 2007).
4. Haute Autorite de santé via http://www.has-sante.fr/portail/ upload/docs/application/pdf/ri-ct-2005-v.04-10-06.pdf (accessed Jan 17th 2007).
5. College voor Zorgverzekering, Procedure aanvraag vergoeding geneesmiddelen, via http://www.cvz.nl/resources/CFH-beoordelingscriteria-tcm28- 15811.pdf (accessed Jan 17th 2007)
6. National Institute for Clinical Excellence, via http://www.nice.org.uk/ page.aspx?o=201971 (accessed Jan 17th 2007).
7. th 2008).
8. nd 2007).
9. European Medicines Evaluation Agency, Guidelines, via http://www.emea.europa.eu/htms/human/humanguidelines/efficacy.htm.
10. Rothwell PM. Treating Individuals 1.External validity of randomised controlled trials:"To whom do the results of this trial apply?". Lancet 2005; 365:82-93.
11. Gotzsche PC. Believability of relative risks and odds ratios in abstracts: cross sectional study. BMJ 2006; 333: 231-4.
12. MacMahon S, Colins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001; 357: 455-62.
13. Horn SD. Performance Measures and Clinical Outcome. JAMA 2006; 296(22): 2731-2.
14. nd 2007).
15. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Cont Clin Trials 1996;17:1-12.
16. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334-6.
17. th 2008).
18. nd 2007).
19. Joppi R, Bertele V, Garattini S, et al. Disappointing Biotech. BMJ 2005;331:895-7
20. nd 2007).
21. th 2004.
22. nd 2007).
23. Simoens S, De Coster S. Sustaining generic medicines markets in Europe. Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmaco-economics, April 2006.
24. Detsky AS, Laupacis A. Relevance of Cost-effectiveness Analysis to Clinicians and Policy MakersJAMA 2007; 298:221-4.
25. nd 2007).